The Impact of SARS-CoV-2 Infection on Symptom Control and Lung Function in Children with Asthma.

IF 6.8 2区 医学 Q1 RESPIRATORY SYSTEM
Kristina Gaietto, Nicholas Bergum, Natalia Acevedo-Torres, Oliver Snyder, Leigh Anne DiCicco, Gabriella Butler, Sherry Rauenswinter, Jennifer Iagnemma, David Wolfson, Traci M Kazmerski, Erick Forno
{"title":"The Impact of SARS-CoV-2 Infection on Symptom Control and Lung Function in Children with Asthma.","authors":"Kristina Gaietto, Nicholas Bergum, Natalia Acevedo-Torres, Oliver Snyder, Leigh Anne DiCicco, Gabriella Butler, Sherry Rauenswinter, Jennifer Iagnemma, David Wolfson, Traci M Kazmerski, Erick Forno","doi":"10.1513/AnnalsATS.202302-117OC","DOIUrl":null,"url":null,"abstract":"<p><p><b>Rationale:</b> Little is known about the long-term impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on children with asthma. <b>Objectives:</b> To determine whether SARS-CoV-2 infection affects symptom control and lung function in children with asthma. <b>Methods:</b> Using data from clinical registries and the electronic health record, we conducted a prospective case-control study of children with asthma aged 6-21 years who had (cases) or did not have (control subjects) SARS-CoV-2 infection, comparing baseline and follow-up asthma symptom control and spirometry within an ∼18-month time frame and, for cases, within 18 months of acute coronavirus disease (COVID-19). <b>Results:</b> A total of 171 cases had baseline and follow-up asthma symptom data, and 114 cases had baseline and follow-up spirometry measurements. There were no significant differences in asthma symptom control (<i>P</i> = 0.50), forced expiratory volume in 1 second (<i>P</i> = 0.47), forced vital capacity (<i>P</i> = 0.43), forced expiratory volume in 1 second/forced vital capacity (<i>P</i> = 0.43), or forced expiratory flow, midexpiratory phase (<i>P</i> = 0.62), after SARS-CoV-2 infection. Compared with control subjects (113 with symptom data and 237 with spirometry data), there were no significant differences in follow-up asthma symptom control or lung function. A similar proportion of cases and control subjects had poorer asthma symptom control (17.5% vs. 9.7%; <i>P</i> = 0.07) or worse lung function (29.0% vs. 32.5%; <i>P</i> = 0.50) at follow-up. Patients whose asthma control worsened after COVID-19 had a shorter time to follow-up (3.5 [1.5-7.5] vs. 6.1 [3.1-9.8] mo; <i>P</i> = 0.007) and were more likely to have presented with an asthma exacerbation during COVID-19 (46% vs. 26%; <i>P</i> = 0.04) than those without worse control. <b>Conclusions:</b> We found no significant differences in asthma symptom control or lung function in youth with asthma up to 18 months after acute COVID-19, suggesting that COVID-19 does not affect long-term asthma severity or control in the pediatric population.</p>","PeriodicalId":8018,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":"1605-1613"},"PeriodicalIF":6.8000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632927/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the American Thoracic Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1513/AnnalsATS.202302-117OC","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale: Little is known about the long-term impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on children with asthma. Objectives: To determine whether SARS-CoV-2 infection affects symptom control and lung function in children with asthma. Methods: Using data from clinical registries and the electronic health record, we conducted a prospective case-control study of children with asthma aged 6-21 years who had (cases) or did not have (control subjects) SARS-CoV-2 infection, comparing baseline and follow-up asthma symptom control and spirometry within an ∼18-month time frame and, for cases, within 18 months of acute coronavirus disease (COVID-19). Results: A total of 171 cases had baseline and follow-up asthma symptom data, and 114 cases had baseline and follow-up spirometry measurements. There were no significant differences in asthma symptom control (P = 0.50), forced expiratory volume in 1 second (P = 0.47), forced vital capacity (P = 0.43), forced expiratory volume in 1 second/forced vital capacity (P = 0.43), or forced expiratory flow, midexpiratory phase (P = 0.62), after SARS-CoV-2 infection. Compared with control subjects (113 with symptom data and 237 with spirometry data), there were no significant differences in follow-up asthma symptom control or lung function. A similar proportion of cases and control subjects had poorer asthma symptom control (17.5% vs. 9.7%; P = 0.07) or worse lung function (29.0% vs. 32.5%; P = 0.50) at follow-up. Patients whose asthma control worsened after COVID-19 had a shorter time to follow-up (3.5 [1.5-7.5] vs. 6.1 [3.1-9.8] mo; P = 0.007) and were more likely to have presented with an asthma exacerbation during COVID-19 (46% vs. 26%; P = 0.04) than those without worse control. Conclusions: We found no significant differences in asthma symptom control or lung function in youth with asthma up to 18 months after acute COVID-19, suggesting that COVID-19 does not affect long-term asthma severity or control in the pediatric population.

严重急性呼吸系统综合征冠状病毒2型感染对哮喘儿童症状控制和肺功能的影响。
理由:人们对严重急性呼吸系统综合征冠状病毒2型感染对哮喘儿童的长期影响知之甚少。目的:确定严重急性呼吸系统综合征冠状病毒2型感染是否影响哮喘儿童的症状控制和肺功能。方法:利用来自临床登记和电子健康记录(EHR)的数据,我们对6-21岁患有严重急性呼吸系统综合征冠状病毒2型感染(病例)和未感染(对照)的哮喘儿童进行了前瞻性病例对照研究,比较了基线和随访哮喘症状控制和肺活量测定,在约18个月的时间内,对于病例,在急性新冠肺炎的18个月内。结果:共有171例患者有哮喘症状基线和随访数据,114例患者有肺活量基线和随访测量数据。严重急性呼吸系统综合征冠状病毒2型感染后,哮喘症状控制(p=0.50)、FEV1(p=0.47)、FVC(p=0.43)、FEV1/FVC(p=0.043)或FEF25-75(p=0.62)没有显著差异。与对照组(113例有症状数据,237例有肺活量测定数据)相比,随访哮喘症状控制或肺功能没有显著差异。随访时,相似比例的病例和对照组的哮喘症状控制较差(17.5%vs 9.7%,p=0.07)或肺功能较差(29.0%vs 32.5%,p=0.05)。新冠肺炎后哮喘控制恶化的患者的随访时间更短(3.5[1.5-7.5]对6.1[3.1.9.8]个月,p=0.007),并且与未得到更差控制的患者相比,更有可能在新冠肺炎期间出现哮喘恶化(46%对26%,p=0.04)。结论:在急性新冠肺炎后18个月内,我们发现患有哮喘的青少年在哮喘症状控制或肺功能方面没有显著差异,这表明新冠肺炎不会影响儿科人群的长期哮喘严重程度或控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of the American Thoracic Society
Annals of the American Thoracic Society Medicine-Pulmonary and Respiratory Medicine
CiteScore
9.30
自引率
3.60%
发文量
0
期刊介绍: The Annals of the American Thoracic Society (AnnalsATS) is the official international online journal of the American Thoracic Society. Formerly known as PATS, it provides comprehensive and authoritative coverage of a wide range of topics in adult and pediatric pulmonary medicine, respiratory sleep medicine, and adult medical critical care. As a leading journal in its field, AnnalsATS offers up-to-date and reliable information that is directly applicable to clinical practice. It serves as a valuable resource for clinical specialists, supporting their formative and continuing education. Additionally, the journal is committed to promoting public health by publishing research and articles that contribute to the advancement of knowledge in these fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信